Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Exclusion Criteria

• •a clinically important event that would interfere with study schedule or procedure or compromise subject safety
• •a diagnosis of hypereosinophilic syndrome
• •an underlying lung disorder
• •a current smoker
• •use of systemic immunosuppressive agents within 6 months of study
• •current use of systemic corticosteroids
• •received attenuated live attenuated vaccines within three months prior to study entry
• •expected to be poorly compliant with study drug, procedures, visits
• •aggravating factors that are inadequately controlled
• •participation in any investigational drug or device study within 30 days prior to study entry
• •participation in biologics study within 3 months prior to study entry
• •receipt of anti-human interleukin-5 (hIL-5) antibody within 6 months of study entry
• •female subjects who are pregnant or nursing
• •concurrent infection or disease that may preclude assessment of eosinophilic esophagitis
• •concurrent immunodeficiency (human immunodeficiency \[HIV\], or acquired immunodeficiency syndrome \[AIDS\] or congenital immunodeficiency).
• •current suspected drug and/or alcohol abuse